Idiopathic inflammatory myopathies (IIM), which are generally referred to as myositis, are a group of rare, chronic autoimmune diseases that are characterized by progressive muscle weakness and damage to joints and major organs. Despite advancements in diagnosis, there are currently no treatment options specifically approved to treat most types of IIM, and the disease continues to have a profound effect on patients’ quality of life.
It is currently estimated that 5-10 people per million are diagnosed with a type of IIM each year. IIM can affect people of any age or gender.
5-10 people per million are diagnosed with a type of Idiopathic inflammatory myopathies each year.
J&J’s approach to idiopathic inflammatory myopathies (IIM)
Challenges remain in the disease management of IIM, and there is a great need to develop new approved treatments with proven safety profiles.
Building on our legacy of leadership in immunology innovation, we are currently evaluating an immunoselective treatment, designed to potentially address the underlying cause of the disease without impacting other immune functions. This investigational therapy is being studied across multiple auto- and alloantibody-driven diseases, including IIM.
